BASLISIRAN
UNII 9W9NX4UL6N

Substance Identification & Data

This profile provides standardized clinical and technical data for Baslisiran, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 9W9NX4UL6N.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3080217-81-5 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

9W9NX4UL6N

CAS Registry Number

3080217-81-5

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

BASLISIRAN

Official standardized name for this substance within the FDA UNII nomenclature system.

INN ID

14092

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Baslisiran

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Baslisiran. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Baslisiran

Common Names & Synonyms

O-[(2R,3S)-2-(hydroxymethyl)oxolan-3-yl hydrogen all-P-ambo-5′-O-[{[(2R,3S)-3-{[{[1-(1-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-9,13-bis{2-[(2-{2-[(2-acetamido-2-deoxy-β-Dgalactopyranosyl)oxy]ethoxy}ethyl)amino]-2-oxoethyl}-7,14-dioxo-3-oxa-6,9,13-triazaoctadecan-18-oyl)piperidin-4-yl]oxy}(hydroxy)phosphorothioyl]oxy}oxolan-2-yl]methoxy}(hydroxy)phosphorothioyl]-2′-O-methylcytidylyl-(3′→5′)-2′-O-methyladenylyl-(3′→5′)-2′-O-methylcytidylyl-(3′→5′)-2′-O-methylcytidylyl-(3′→5′)-2′-O-methyladenylyl-(3′→5′)-2′-O-methylguanylyl-(3′→5′)-2′-O-methylcytidylyl-(3′→5′)-2′-O-methyluridylyl-( 3′→5′)-2′-deoxy-2′-fluorouridylyl-(3′→5′)-2′-O-methylguanylyl-(3′→5′)-2′-deoxy-2′-fluorouridylyl-(3′→5′)-2′-O-methyluridylyl-(3′→5′)-2′-deoxy-2′-fluorouridylyl-(3′→5′)-2′-O-methylguanylyl-(3′→5′)-2′-O-methyluridylyl-(3′→5′)-2′-O-methylguanylyl-(3′→5′)-2′-O-methyladenylyl-(3′→5′)-2′-O-methyladenylyl-(3′→5′)-2′-O-methyladenylyl-(3′→5′)-2′-O-methylcytidylyl-(3′→5′)-2′-O-methyl-P-thio-3′-adenylate, duplex with all-P-ambo-2′-O-methyl-P-thioguanylyl-(5′→3′)-2′-O-methyl-P-thiouridylyl-(5′→3′)-2′-O-methylguanylyl-(5′→3′)-2′-O-methylguanylyl-(5′→3′)-2′-O-methyluridylyl-(5′→3′)-2′-deoxy-2′-fluorocytidylyl-(5′→3′)-2′-O-methylguanylyl-(5′→3′)-2′-deoxy-2′-fluoroadenylyl-(5′→3′)-2′-O-methyladenylyl-(5′→3′)-2′-deoxy-2′-fluorocytidylyl-(5′→3′)-2′-O-methyladenylyl-(5′→3′)-2′-O-methyladenylyl-(5′→3′)-2′-O-methyladenylyl-(5′→3′)-2′-O-methylcytidylyl-(5′→3′)-2′-deoxy-2′-fluoroadenylyl-(5′→3′)-2′-O- methylcytidylyl-(5′→3′)-2′-O-methyluridylyl-(5′→3′)-2′-O-methyluridylyl-(5′→3′)-2′-O-methyl-P-thiouridylyl-(5′→3′)-2′-deoxy-2′-fluoro-P-thioguanylyl-(5′→3′)-2′-O-methyluridine

RNA, ([1′-de(6-amino-9H-purin-9-yl)]dA-(5′→5′)-sp-Cm-Am-Cm-Cm-Am-Gm-Cm-Um-(2′-deoxy-2′-fluoro)U-Gm-(2′-deoxy-2′-fluoro)U-Um-(2′-deoxy-2′-fluoro)U-Gm-Um-Gm-Am-Am-Am-Cm-Am-(3′→3′)-sp-[1′-de(6-amino-9H-purin-9-yl)]dA), 3′-[O-[1-[18-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-6,10-bis[2-[[2-[2-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]ethoxy]ethyl]amino]-2-oxoethyl]-1,5,12-trioxo-16-oxa-6,10,13-triazaoctadec-1-yl]-4-piperidinyl] hydrogen phosphorothioate], complex with RNA (Um-sp-(2′-deoxy-2′-fluoro)G-sp-Um-Um-Um-Cm-(2′-deoxy-2′-fluoro)A-Cm-Am-Am-Am-(2′-deoxy-2′-fluoro)C-Am-(2′-deoxy-2′-fluoro)A-Gm-(2′-deoxy-2′-fluoro)C-Um-Gm-Gm-sp-Um-sp-Gm) (1:1)

baslisiran [INN]

External Clinical & Regulatory Resources

Previous UNII9W9GSK98YL

Next UNII9W9P6W6C4R